Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform

Información del proyecto

MEDMICO

Identificador del acuerdo de subvención: 666676

DOI

10.3030/666676

Proyecto cerrado

Fecha de la firma de la CE 2 Junio 2015

Fecha de inicio 1 Julio 2015

Fecha de finalización 31 Diciembre 2018

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 4 487 525,00

Aportación de la UE

€ 4 487 525,00

Coordinado por

RADISENS DIAGNOSTICS LIMITED
Ireland

Periodic Reporting for period 3 - MEDMICO (Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform)

Período documentado: 2018-01-01 hasta 2018-12-31

Resumen del contexto y de los objetivos generales del proyecto

Diabetes affects 8.5% (2013) of the adult European population rising to 10.3% (2035) and is associated with co-morbid conditions such as cardiovascular and renal abnormalities. These lead to diabetic complications, ischemic heart disease, heart failure and kidney failure. Management of this growing epidemic requires a shift in care management and delivery, away from central lab testing. The majority of current diagnostic monitoring for diabetes, heart disease, kidney disease and their associated complications still involves large needles and vials of blood being transported to central laboratories for testing and long waits for results.

To address the need for instant testing of any chronic disease from a finger-prick of blood on a single blood testing device, Radisens Diagnostics proposed the MEDMICO project, to develop the worlds first PoCT platform integrating the primary blood testing families of immunoassays, turbidimetry and clinical chemistry. The European Commission have funded this project (proposal number: SEP-210218471) under the H2020 call H2020-SMEINST-2-2014, Topic: PHC-12-2014.

Under MEDMICO, HbA1c, Lipids and Kidney tests will be integrated on to a single diabetes comorbid platform for improved patient monitoring within primary care, outpatient clinics and pharmacy settings. This will improve patient outcomes and healthcare efficiencies, positioning Europe at the forefront of healthcare innovation and deliver an efficient platform to combat this diabetes epidemic.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Several deliverables have been submitted during this second period to EASME for their confidential review by industry experts. All deliverables due have been submitted. These summarise the first and second phases of the platform design, development, integration and verification of the target chronic disease panels onto the Gemini platform, with method comparison data and manufacturing process development progress.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

MEDMICO will integrate panels for diabetes, cardiovascular disease and kidney disease onto its multi-mode Gemini point of care platform, delivering central laboratory performance, room temperature storage and removing the need for over-night fasting by patients. MEDMICO plans to tackle the lack of access to clinical diagnostics to society by integrating multiple clinical diagnostic needs within one multi-mode device, offering ease of use and simplified logistics,. This addresses the lack of access by empowering decentralised healthcare settings to embrace this novel platform. MEDMICO will aim to go further by targeting the pharmacy sector, thereby opening the possibility of weekend healthcare access to society. Providing greater access to healthcare for chronic disease sufferers, with a single healthcare visit and immediate diagnostic results will positively impact society, thereby improving patient outcomes, lowering chronic risk factors and will reduce the huge burden on healthcare system resources.

MEDMICO Logo